Company Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States.
The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19.
The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014.
Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
| Country | United States |
| IPO Date | Apr 15, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Dr. Jeffrey L. Stein Ph.D. |
Contact Details
Address: 6310 Nancy Ridge Drive San Diego, California United States | |
| Website | https://www.cidara.com |
Stock Details
| Ticker Symbol | CDTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001610618 |
| CUSIP Number | 171757107 |
| ISIN Number | US1717571079 |
| Employer ID | 46-1537286 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeffrey L. Stein Ph.D. | President, Chief Executive Officer & Executive Director |
| Dr. Preetam Shah M.B.A., Ph.D. | Chief Financial Officer & Principal Accounting Officer |
| Shane M. Ward | Chief Operating Officer & Corporate Secretary |
| Allison Lewis CCP, SPHR | Senior Vice President of People & Culture |
| Dr. Kevin M. Forrest Ph.D. | Founder & Chief Strategy Officer |
| Dr. Leslie Tari Ph.D. | Chief Scientific Officer |
| Dr. Nicole Davarpanah J.D., M.D. | Senior Vice President of Translational Research & Development |
| Dr. Taylor Sandison M.D., M.P.H. | Chief Medical Officer |
| Jim Beitel M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 09, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Dec 04, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Dec 03, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 29, 2024 | 4 | Filing |
| Nov 26, 2024 | SC 13D/A | [Amend] Filing |
| Nov 26, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 8-K | Current Report |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Oct 02, 2024 | 4 | Filing |